EFFECT OF PULSED MAGNETIC FIELDS ON THE EXPRESSION LEVELS OF TUMOR SUPPRESSOR GENES IN HUMAN T98G GLYOBLASTOMA CELL LINE
Yu. S. Sidorenko,
O. I. Kit,
I. A. Popov,
A. I. Shikhlyarova,
E. E. Rostorguev,
N. N. Timoshkina,
M. A. Gusareva,
Yu. Yu. Arapova,
D. S. Potemkin,
A. A. Pushkin,
V. V. Stasov https://doi.org/10.21294/1814-4861-2019-18-6-57-66
Abstract
Aim: to study the effect of a pulsed magnetic field (PMF) on the expression of key tumor suppressor genes, such as aPc, MLH, and MGMt in human t98G glioblastoma cell line. material and methods. the PMF with the intensity of 15 and 300 mt was used alone and in combination with ionizing radiation at a single dose of 10 Gy. to perform ionizing radiation, theratron Equinox 60co unit Best theratronics Ltd., Ottawa, canada) was used. the source of the pulsed magnetic field was Neuro-Ms / D therapeutic advanced device of the Neurosoft company. Live and dead cells were determined in NanoEntekJuliFl cell counter (Korea) using a 0.4 % trypan blue solution to stain dead cells. total RNa was extracted according to the protocol of the manufacturer trizol with changes: the aqueous phase was separated with trizol reagent twice. the quantitative measurement of the isolated RNa was carried out on a Qubit 2.0 fluorimeter using a kit of reagents with the Quant-it RNa assayKit RNa intercalating dye (Life technologies, usa). the expression of MLH, aPc, and MGMt genes was evaluated by Rt-PcR using a cFx96 amplifier (BioRad, usa). Data were analyzed using the cycle threshold (ct) method with normalization for tBP gene expression in each sample. Relative expression of the genetic locus (Exp) was calculated by the 2-Δct method. statistical analysis of the results was carried out using the statictica v10 software package. Results. One day after exposure to PMF, significant differences in the MGMt expression level compared to the control were found (p<0.05). a significant decrease in the transcriptional activity of the MGMt gene in glioblastoma cells was observed with PMF intensity of 15 mt, and correlated with the cell mortality rate. No changes in the mortality rate were observed after radiation exposure combined with 15 mt PMF. However, the mortality rate decreased from 18.7 % to 15 % after radiation exposure combined with 300 mt PMF. Conclusion. the effect of reduction in the transcriptional activity of MGMt in t98G glioblastoma cells and the effect of PMF as a monofactor on their viability characterize the magnetic susceptibility of tumor cell mechanisms. Given the multidirectional nature of the combined interaction of ionizing radiation and PMF, it is necessary to emphasize the importance of choosing and justifying the role of biotropic parameters of PMF in order to exclude a negative effect on the treatment.
About the Authors
Yu. S. Sidorenko
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
MD, Professor, Member of the Russian Academy of Sciences
Author ID (Scopus): 6603967956
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
O. I. Kit
Rostov Research Institute of Oncology
Russian Federation
MD, Professor, Corresponding Member of the Russian Academy of Sciences, General Director
ResearcherID (WOS): U-2241-2017. Author ID (Scopus): 55994103100 Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Russian Federation
MD, Professor, Corresponding Member of the Russian Academy of Sciences, General Director
ResearcherID (WOS): U-2241-2017. Author ID (Scopus): 55994103100 Russia, 344037, Rostov-on-Don, 14-ya linia, 63
I. A. Popov
Rostov Research Institute of Oncology
Russian Federation
Post-graduate, Oncology Department
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Russian Federation
Post-graduate, Oncology Department
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
A. I. Shikhlyarova
Rostov Research Institute of Oncology
Russian Federation
Professor, Senior Researcher of Experimental Laboratory Center
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Russian Federation
Professor, Senior Researcher of Experimental Laboratory Center
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
E. E. Rostorguev
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
MD, PhD, Head of the Department of Neurooncology,
Author ID (Scopus): 57196005138
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
N. N. Timoshkina
Rostov Research Institute of Oncology
Russian Federation
PhD, Head of the Laboratory Molecular Oncology
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Russian Federation
PhD, Head of the Laboratory Molecular Oncology
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
M. A. Gusareva
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
MD, PhD, Head of the Radiology Department
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Yu. Yu. Arapova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
PhD, Researcher, Experimental Laboratory Center
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
D. S. Potemkin
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
A. A. Pushkin
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology
AuthorID (Scopus): 57200548010
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
V. V. Stasov
Rostov Research Institute of Oncology
Russian Federation
PhD, expert-physicist for the control of ionizing and non-ionizing radiation sources of radiology Department
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
Russian Federation
PhD, expert-physicist for the control of ionizing and non-ionizing radiation sources of radiology Department
Russia, 344037, Rostov-on-Don, 14-ya linia, 63
References
1. Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol. 2018 Oct 1; 20(suppl_4): iv1iv86. doi: 10.1093/neuonc/noy131.
2. Pervichnye opukholi tsentral’noi nervnoi sistemy. Klinicheskie rekomendatsii Ministerstva zdravookhraneniya Rossiiskoi Federatsii, 2018. URL: http://cr.rosminzdrav.ru/#!/recomend/853. (cited 17.05.2019). (in Russian).
3. Zhu P., Zhu J.J. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. Chin Clin Oncol. 2017 Aug; 6(4): 41. doi: 10.21037/cco.2017.06.29.
4. Ulashchik V.S. Magnet therapy: current understanding of mechanisms of magnet field action on body. Healthcare. 2015; 11: 21–29. (in Russian).
5. Gurko T.S. Magnetic therapy application in the rehabilitation of patients with multiple sclerosi. Tambov University Reports. Series Natural and Technical Sciences. 2015; 20(3): 545–546. (in Russian).
6. Kutashov V.A., Shulga A.S. Transcranial magnetic therapy in neurological clinic. Central Scientific Herald. 2016; 1(12): 9–11. (in Russian).
7. Falone S., Grossi M.R., Cinque B., D’Angelo B., Tettamanti E., Cimini A., Di Ilio C., Amicarelli F. Fifty hertz extremely low-frequency electromagnetic field causes changes in redox and differentiative status in neuroblastoma cells. Int J Biochem Cell Biol. 2007; 39(11): 2093–2106. doi: 10.1016/j.biocel.2007.06.001.
8. Destefanis M., Viano M., Leo C., Gervino G., Ponzetto A., Silvagno F. Extremely low frequency electromagnetic fields affect proliferation and mitochondrial activity of human cancer cell lines. Int J Radiat Biol. 2015; 91(12): 964–72. doi: 10.3109/09553002.2015.1101648.
9. Marchesi N., Osera C., Fassina L., Amadio M., Angeletti F., Morini M., Magenes G., Venturini L., Biggiogera M., Ricevuti G., Govoni S., Caorsi S., Pascale A., Comincini S. Autophagy Is Modulated in Human Neuroblastoma Cells Through Direct Exposition to Low Frequency Electromagnetic Fields. J Cell Physiol. 2014 Nov; 229(11): 1776–86. doi: 10.1002/jcp.24631.
10. Storch K., Dickreuter E., Artati A., Adamski J., Cordes N. BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage. PLoS One. 2016; 11(12): e0167931. doi: 10.1371/journal.pone.0167931.
11. Popov I.A., Shikhliarova A.I., Rostorguev E.E., Gusareva M.A., Timoshkina N.N., Potemkin D.S., Arapova Yu. Yu., Stasov V.V. Nhibiting influence of impulse magnetic fields and ionizing radiation on the culture of human T98G glioblastoma cells. Medical news of the north Caucasus. 2019; 14 (12): 228–231. (in Russian). doi: 10.14300/mnnc.2019.14021.
12. Mitra S. MGMT: A personal perspective. DNA Repair (Amst). 2007 Aug 1; 6(8): 1064–70.
13. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000 Apr; 462(2–3): 83–100. doi: 10.1016/s1383-5742-(00)00017-x.
14. Lukash L.L., Man’ko V.G., Lylo V.V. Role of O-alkylguanine-DNA alkyltransferase in repairing lesions, induced by alkylating compounds. Biopolymers and Cell. 2001; 17(4): 265–277. doi: 10.7124/bc.0005B7.
15. Bell E.H., Zhang P., Fisher B.J., Macdonald D.R., McElroy J.P., Lesser G.J., Fleming J., Chakraborty A.R., Liu Z., Becker A.P., Fabian D., Aldape K.D., Ashby L.S., Werner-Wasik M., Walker E.M., Bahary J.P., Kwok Y., Yu H.M., Laack N.N., Schultz C.J., Gray H.J., Robins H.I., Mehta M.P., Chakravarti A. Association ofMGMTpromoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide an analysis from the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018 Oct 1; 4(10): 1405–1409. doi: 10.1001/jamaoncol.2018.1977.
16. Matsko M.V. Drug treatment of brain tumors. Practical oncology. 2013; 14(3): 166–174. (in Russian).
17. Kontic M., Stojsic J., Jovanovic D., Bunjevacki V., Ognjanovic S., Kuriger J., Puumala S., Nelson H.H. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathological characteristics of primary non small cell lung carcinoma. Clin Lung Cancer. 2012 Jul; 13(4): 297–303. doi: 10.1016/j.cllc.2011.11.003.
18. Kit O.I., Vodolazhskiy D.I., Dvadnenko K.V., Efimova I.Yu., Oleynikova E.N., Oleynikov D.D., Timoshkina N.N. Aberrant methylation of the promoter of APC, CDH13 and MGMT genes in colorectal cancer patients. Siberian Journal of Oncology. 2016; 15(2): 48–55. (in Russian). doi: 10.21294/1814-4861-2016-15-2-48-55.
Review
For citations:
Sidorenko Yu.S., Kit O.I., Popov I.A., Shikhlyarova A.I., Rostorguev E.E., Timoshkina N.N., Gusareva M.A., Arapova Yu.Yu., Potemkin D.S., Pushkin A.A., Stasov V.V. EFFECT OF PULSED MAGNETIC FIELDS ON THE EXPRESSION LEVELS OF TUMOR SUPPRESSOR GENES IN HUMAN T98G GLYOBLASTOMA CELL LINE. Siberian journal of oncology. 2019;18(6):57-66. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-6-57-66
Views:
980
Email this article 
